Corcept Therapeutics is trading 4.05% lower at $108.78 on October 16, 2026, amid pressure on risk-sensitive stocks as biotech and broader markets decline.
- XBI was down 2.06%, alongside declines in the S&P 500 and Nasdaq.
- A report announced FDA approval of Corcept’s Lifyorli for certain ovarian cancers on October 16, a positive development that does not explain the share-price drop. Available coverage found no company-specific negative catalyst.